Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.54 |
| ▸ | GRPR | P30550 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396822 | 0.97 | NPBWR1 (0.61) | NPBWR1IL23RRXFP1PTH1R | |
| SCHEMBL30874395 | 0.95 | NPBWR1 (0.56) | NPBWR1IL23RRXFP1KISS1RGRPR | |
| SCHEMBL30377378 | 0.95 | KISS1R (0.56) | NPBWR1IL23RRXFP1KISS1RPTH1R | |
| SCHEMBL15849869 | 0.94 | NPBWR1 (0.55) | NPBWR1IL23RRXFP1KISS1RGRPR | |
| SCHEMBL677586 | 0.94 | NPBWR1 (0.56) | NPBWR1IL23RRXFP1KISS1ROPRD1 | |
| SCHEMBL29375423 | 0.94 | NPBWR1 (0.56) | NPBWR1IL23RRXFP1KISS1ROPRD1 | |
| SCHEMBL29988116 | 0.93 | NPBWR1 (0.61) | NPBWR1IL23RRXFP1PTH1R | |
| SCHEMBL31226860 | 0.92 | NPBWR1 (0.64) | NPBWR1IL23RRXFP1 | |
| SCHEMBL31294865 | 0.92 | NPBWR1 (0.61) | NPBWR1IL23RRXFP1PTH1R | |
| SCHEMBL30598170 | 0.92 | NPBWR1 (0.61) | NPBWR1IL23RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | claimed |
| WO-2025093774-A1 | GLUCAGON-LIKE PEPTIDE 1 AGONISTS | Constructive Biology Limited (GB) | 2025-05-08 | — | — | WO | claimed |
| EP-4345104-B1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-08-28 | — | — | EP | claimed |
| WO-2024068827-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-04-04 | — | — | WO | claimed |
| EP-4326330-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | Novartis AG (CH) | 2024-02-28 | — | — | EP | claimed |
| WO-2023012709-A1 | AN IMPROVED PROCESS FOR FMOC SYNTHESIS OF SEMAGLUTIDE | USV PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | claimed |
| WO-2022224164-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | NOVARTIS AG (CH) | 2022-10-27 | — | — | WO | claimed |
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| EP-4602064-A1 | METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE | Bachem Holding AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| CN-118791551-B | Liquid phase synthesis method of semaglutin dipeptide fragment | 质肽药业(泰州)有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119161410-A | Synthesis method of semaglutin dipeptide fragment | 质肽药业(泰州)有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-3704143-B1 | CHEMO-ENZYMATIC SYNTHESIS OF LIRAGLUTIDE, SEMAGLUTIDE AND GLP-1 | FRESENIUS KABI IPSUM S R L (IT) | 2023-10-18 | — | — | EP | disclosed |
| EP-4188355-A2 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | Delta 4 GmbH (AT) | 2023-06-07 | — | — | EP | disclosed |
| CN-116120426-A | Method for purifying liraglutide oxidized impurities | 江苏诺泰澳赛诺生物制药股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023012829-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022224164-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | NOVARTIS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| EP-4073096-A1 | A METHOD OF FORMING A CONJUGATE OF A SULFONAMIDE AND A POLYPEPTIDE | SANOFI (FR) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022023533-A2 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | DELTA 4 GMBH (AT) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | GLP1R, IAPP, VIP | NPBWR1 785/4885IL23R 1461/4885RXFP1 83/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | NPBWR1 188/4885IL23R 3237/4885RXFP1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.